Filter your results
- 3
- 3
- 3
- 2
- 1
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort studyAlimentary Pharmacology & Therapeutics (Suppl), 2020, 52 (3), pp.500-512. ⟨10.1111/apt.15901⟩
Journal articles
hal-03933002v1
|
||
Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosisJournal of Hepatology, 2022, 76 (2), pp.464-469. ⟨10.1016/j.jhep.2021.10.012⟩
Journal articles
hal-04012236v1
|
|||
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertensionJournal of Hepatology, 2022, 77 (6), pp.1525-1531. ⟨10.1016/j.jhep.2022.07.016⟩
Journal articles
hal-04013314v1
|